Medication info
ActoZone Met Tablets 15/850 mg

ActoZone Met Tablets 15/850 mg

Prescription medicationTablet
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
White to grayish-white oblong film-coated tablets
Packaging
30 tablets/PPT[(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 201907392 · Approved 2019.10.22 · Insurance code 645406120

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The starting dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the dose of metformin or pioglitazone the patient is currently receiving. Start with 1 tablet daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their existing doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes mellitus may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of this medicine. After administration of this medicine or an increase in dose, patients must be carefully monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG does not worsen, administration for an adequate period (8-12 weeks) is recommended to assess changes in HbA1C.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes when used in conjunction with diet and exercise, aiding in effective blood sugar management.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The starting dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the dose of metformin or pioglitazone the patient is currently receiving. Start with 1 tablet daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their existing doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes mellitus may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of this medicine. After administration of this medicine or an increase in dose, patients must be carefully monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG does not worsen, administration for an adequate period (8-12 weeks) is recommended to assess changes in HbA1C.

Precautions

This medication assists in controlling blood sugar levels. It can cause a rare but severe condition known as lactic acidosis, so patients with impaired kidney function or heart disease should exercise particular caution. Additionally, patients with impaired liver function or those who consume excessive alcohol should avoid this medication, as it may pose risks. This medication can exacerbate heart issues such as congestive heart failure, so individuals with symptoms of heart failure or severe heart conditions should not use it. If there is a history of bladder cancer or symptoms related to the bladder (such as hematuria or urinary dysfunction), immediate consultation with a physician is necessary, and bladder cancer patients should refrain from taking this medication. For patients with diminished kidney function or at risk of acute kidney failure, administration of this medication should be discontinued or used cautiously, with regular kidney function tests required. This medication may cause hypoglycemia, particularly when taken with other blood sugar-lowering agents, so careful monitoring of blood sugar changes is advised. If undergoing surgery or receiving testing involving contrast agents, temporarily discontinue this medication and resume only after confirming normal kidney function. Pregnant or nursing women should not take this medication, and safety in pediatric patients has not been established. Elderly patients have a higher risk of worsened kidney function, thus dosage should be adjusted carefully and kidney function should be monitored regularly. While taking this medication, maintain regular meals and appropriate exercise, and have regular blood sugar and blood tests done. In the event of an overdose, seek immediate medical assistance, and blood dialysis may be necessary.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • weakness
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 38 more
  • upper respiratory tract infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • vision reduction
  • liver failure
  • congestive heart failure
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • intra-abdominal gas retention
  • elevated serum creatinine
  • increased blood urea
  • fractures
  • ovulation
  • liver function abnormalities
  • macular edema
  • abnormal blood glucose
  • failed blood glucose control
  • hypoglycemia
  • gross hematuria
  • urinary incontinence
  • urgency incontinence

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and humidity, so it must be stored in a sealed container. It's recommended to keep the storage temperature between 1 and 30 degrees Celsius to safely maintain the medication's efficacy.

Appearance and packaging

Appearance

White to grayish-white oblong film-coated tablets

Package unit

30 tablets/PPT[(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.